In Vitro Toxicity Market Overview :
In Vitro Toxicity is a scientific method of testing toxic chemical substances on cultured bacteria or mammalian cells. Drug toxicity is the major reason for withdrawal of drugs from the market which causes a company huge amount of financial costs and losses. Hepatotoxicity and cardiotoxicity are the most recurring drug toxicity. In Vitro toxicity involve assays of cultured bacteria or mammalian cells. This diverse assays covers a range of potential toxic events which help in drug testing. This method has been heavily used in drug testing since there have been regulation of testing drugs on animals. In vitro toxicity is also used in identification of harmful chemicals in agricultural products, therapeutics drugs, and food additives.
The In Vitro toxicity market is currently at its blooming stage. The global in vitro toxicity market is expected to register substantial growth in near future attributed to opposition to testing of toxic chemicals on animals, new and promising technologies, increasing R&D to detect toxicity of drugs in early stages, Moreover, huge investment made by companies in their R&D department would also attribute in the growth of the market. On the other hand lack of in vitro models to detect autoimmunity and immunostimulation and predictive ability would restrain the growth of the market.
The report segments the global in vitro toxicity market on the basis of dose, absorption, toxic substances and geography. Dose market segment is further classified into dose response and threshold response. Absorption market segment is further classified on the basis of distribution, excretion, and metabolism. Toxic substances market segment is further classified into acute and chronic toxicity, toxin, toxicant, and toxicokinetics. Geographic breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and rest of the world (RoW).
Some of the major companies in In Vitro toxicity market are Agilent Technologies, Inc. (U.S.), Covance, Inc. (A subsidiary of LabCorp) (U.S.), Bio-Rad Laboratories, Inc. (U.S.), General Electric Company (U.S.), Eurofins Scientific SE (Luxembourg), BioReliance, Inc. (A subsidiary of Merck KGaA (Germany), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.), and Cyprotex (U.K.).
The key takeaways from the report
- The report will provide in-depth analysis of In Vitro Toxicity market with respect to major segments such as S1 and S2 of the market.
- The report will include the qualitative and quantitative analysis with market estimation over 2015-2022 and compound annual growth rate (CAGR) between 2016 and 2022.
- Detailed analysis of market dynamics including factors and opportunities.
- An exhaustive regional analysis of In Vitro Toxicity market.
- Profile of key players of the In Vitro Toxicity market, which include key financials, product & services and new developments.
Scope of InVitro Toxicity Market
- Dose Response
- Threshold Response
Toxic Substance Segments
- Acute and chronic toxicity
- North America
- United Kingdom
- South Korea
- South America
- Middle East